Avanos Medical (AVNS) EBITDA (2016 - 2024)
Historic EBITDA for Avanos Medical (AVNS) over the last 12 years, with Q3 2024 value amounting to $12.0 million.
- Avanos Medical's EBITDA rose 90000.0% to $12.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $33.5 million, marking a year-over-year increase of 24895.83%. This contributed to the annual value of $4.2 million for FY2023, which is 8816.9% down from last year.
- Latest data reveals that Avanos Medical reported EBITDA of $12.0 million as of Q3 2024, which was up 90000.0% from $6.3 million recorded in Q2 2024.
- In the past 5 years, Avanos Medical's EBITDA ranged from a high of $16.6 million in Q4 2022 and a low of -$47.2 million during Q4 2020
- Its 5-year average for EBITDA is -$663157.9, with a median of $1.2 million in 2023.
- Data for Avanos Medical's EBITDA shows a peak YoY increase of 350000.0% (in 2021) and a maximum YoY decrease of 216666.67% (in 2021) over the last 5 years.
- Avanos Medical's EBITDA (Quarter) stood at -$47.2 million in 2020, then skyrocketed by 52.54% to -$22.4 million in 2021, then soared by 174.11% to $16.6 million in 2022, then plummeted by 32.53% to $11.2 million in 2023, then grew by 7.14% to $12.0 million in 2024.
- Its last three reported values are $12.0 million in Q3 2024, $6.3 million for Q2 2024, and $4.0 million during Q1 2024.